| 101 |
19800108 | Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer. | 2009 Dec |
1 |
| 102 |
19887555 | Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. | 2009 Nov |
1 |
| 103 |
17885815 | Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu. | 2008 Jan |
2 |
| 104 |
18448999 | Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. | 2008 May |
2 |
| 105 |
18756958 | [Influence of human epidermal growth factor receptor-2 siRNA on chemosensitivity to cisplatin of human ovarian carcinoma cells: an in vitro experiment]. | 2008 Apr 1 |
11 |
| 106 |
18337622 | Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. | 2007 |
1 |
| 107 |
16549824 | Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. | 2006 Apr 20 |
1 |
| 108 |
16638299 | [The effect of siRNA-Her2/neu on the drug sensitivity of Her2/neu-overexpressing lung adenocarcinoma cell line]. | 2006 Jan |
1 |
| 109 |
16681908 | [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2]. | 2006 Mar 7 |
2 |
| 110 |
15703820 | Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. | 2005 Mar |
1 |
| 111 |
15890569 | Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. | 2005 Jun 1 |
1 |
| 112 |
16372489 | High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. | 2005 Dec |
2 |
| 113 |
14998864 | Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. | 2004 Mar |
1 |
| 114 |
15013588 | Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. | 2004 Apr |
1 |
| 115 |
15585076 | Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. | 2004 Dec |
1 |
| 116 |
14512646 | Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. | 2003 |
2 |
| 117 |
11748447 | The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review). | 2002 Jan-Feb |
2 |
| 118 |
11973639 | Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. | 2002 Apr 25 |
2 |
| 119 |
12036454 | Enhanced anti-tumor effect of trastuzumab in combination with cisplatin. | 2002 May |
4 |
| 120 |
12070798 | [Expression of c-erbB-2 and topoisomerase II alpha in relation to chemoresistance in ovarian cancer]. | 2002 Mar |
1 |
| 121 |
12108894 | The current status of docetaxel for metastatic breast cancer. | 2002 Jun |
2 |
| 122 |
12174876 | ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. | 2002 Jul-Aug |
3 |
| 123 |
12452011 | [Synergistic cytotoxic effect of immunotoxin HEL-PE38KDEL and cis-platin against tumor cells]. | 2002 Apr |
1 |
| 124 |
11399867 | Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. | 2001 Jul-Aug |
7 |
| 125 |
11774202 | Targeting HER2: recent developments and future directions for breast cancer patients. | 2001 Dec |
1 |
| 126 |
11899413 | Platinum compounds in the treatment of advanced breast cancer. | 2001 Oct |
2 |
| 127 |
10761709 | Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. | 2000 Feb |
1 |
| 128 |
10781891 | Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. | 2000 Apr 3 |
1 |
| 129 |
10327070 | Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. | 1999 Apr 1 |
2 |
| 130 |
10397267 | Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. | 1999 Jul 1 |
1 |
| 131 |
10482199 | Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. | 1999 Aug |
1 |
| 132 |
10631474 | Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. | 1999 Nov |
1 |
| 133 |
10697535 | Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells. | 1999 Nov-Dec |
11 |
| 134 |
9563896 | Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. | 1998 Apr |
1 |
| 135 |
9662255 | Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. | 1998 Jul |
1 |
| 136 |
9704716 | Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. | 1998 Aug |
4 |
| 137 |
9811454 | Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. | 1998 Oct 29 |
5 |
| 138 |
9845103 | Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. | 1998 Nov 1 |
2 |
| 139 |
9872333 | Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells. | 1998 Dec 17 |
1 |
| 140 |
9150389 | Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway. | 1997 Apr 17 |
4 |
| 141 |
9374379 | Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. | 1997 |
2 |
| 142 |
9493954 | The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. | 1997 |
1 |
| 143 |
8637714 | Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. | 1996 Feb 1 |
2 |
| 144 |
8640763 | Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. | 1996 Mar 1 |
1 |
| 145 |
9816272 | Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. | 1996 Jul |
1 |
| 146 |
7896881 | p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. | 1995 Mar |
2 |
| 147 |
7911565 | Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. | 1994 Jul |
6 |
| 148 |
7913407 | p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. | 1994 Jul 15 |
1 |
| 149 |
1678683 | A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. | 1991 Sep 1 |
1 |